Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients.

Onoda T, Yamauchi H, Yagata H, Tsugawa K, Hayashi N, Yoshida A, Suzuki K, Sakurai O, Nakamura S.

Breast Cancer. 2015 Jul;22(4):406-12. doi: 10.1007/s12282-013-0495-x. Epub 2013 Oct 1.

PMID:
24081457
2.

Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?

Milburn M, Rosman M, Mylander C, Tafra L.

Breast J. 2013 Jul-Aug;19(4):357-64. doi: 10.1111/tbj.12126. Epub 2013 May 23.

PMID:
23701403
3.

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.

BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.

4.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
5.

[Impact of the 21-gene recurrence score assay in clinical treatment and prognosis analysis for patients with hormone receptor positive early-stage breast cancer].

Zhang YN, Zhou YD, Mao F, Guan JH, Lin Y, Wang XJ, Shen SJ, Wang CJ, Yao R, Sun Q.

Zhonghua Zhong Liu Za Zhi. 2018 Feb 23;40(2):110-114. doi: 10.3760/cma.j.issn.0253-3766.2018.02.006. Chinese.

PMID:
29502370
6.

The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.

Kim SJ, Masuda N, Tsukamoto F, Inaji H, Akiyama F, Sonoo H, Kurebayashi J, Yoshidome K, Tsujimoto M, Takei H, Masuda S, Nakamura S, Noguchi S.

Cancer Lett. 2014 Dec 28;355(2):217-23. doi: 10.1016/j.canlet.2014.08.042. Epub 2014 Sep 10.

PMID:
25218592
7.
8.

Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers.

Ono M, Tsuda H, Yunokawa M, Yonemori K, Shimizu C, Tamura K, Kinoshita T, Fujiwara Y.

Breast Cancer. 2015 Mar;22(2):141-52. doi: 10.1007/s12282-013-0464-4. Epub 2013 Apr 13.

PMID:
23584595
9.

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.

Varga Z, Sinn P, Fritzsche F, von Hochstetter A, Noske A, Schraml P, Tausch C, Trojan A, Moch H.

PLoS One. 2013;8(3):e58483. doi: 10.1371/journal.pone.0058483. Epub 2013 Mar 7. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/f715f38e-7aee-4d2b-8bbf-da0411dc6ef3.

10.

Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.

Park S, Park BW, Kim TH, Jeon CW, Kang HS, Choi JE, Hwang KT, Kim IC.

Ann Surg Oncol. 2013 May;20(5):1505-13. doi: 10.1245/s10434-012-2772-x. Epub 2012 Nov 29.

PMID:
23192228
11.

Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR.

J Clin Oncol. 2008 May 10;26(14):2373-8. doi: 10.1200/JCO.2007.14.4287. Epub 2008 Apr 14. Erratum in: J Clin Oncol. 2008 Jun;26(18):3110.

PMID:
18413639
12.

Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?

Poulakaki N, Makris GM, Battista MJ, Böhm D, Petraki K, Bafaloukos D, Sergentanis TN, Siristatidis C, Chrelias C, Papantoniou N.

Breast. 2016 Feb;25:57-61. doi: 10.1016/j.breast.2015.10.007. Epub 2015 Nov 21.

PMID:
26612082
13.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N.

J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29.

PMID:
26926676
14.

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes.

Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, Pruneri G, Mastropasqua MG, Luini A, Bassi F, Pagani G, Viale G, Goldhirsch A.

Breast Cancer Res. 2014 Jun 20;16(3):R65. doi: 10.1186/bcr3679.

15.

Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology.

Karlsson E, Appelgren J, Solterbeck A, Bergenheim M, Alvariza V, Bergh J.

Eur J Cancer. 2014 Nov;50(17):2916-24. doi: 10.1016/j.ejca.2014.08.014. Epub 2014 Sep 17.

PMID:
25241230
16.

A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.

Tang P, Wang J, Hicks DG, Wang X, Schiffhauer L, McMahon L, Yang Q, Shayne M, Huston A, Skinner KA, Griggs J, Lyman G.

Cancer Invest. 2010 Nov;28(9):978-82. doi: 10.3109/07357907.2010.496754.

PMID:
20690804
17.

[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].

Wang SL, Li YX, Song YW, Wang WH, Jin J, Liu YP, Liu XF, Yu ZH.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5. Chinese.

PMID:
21029696
18.

The 21-gene recurrence score and locoregional recurrence in breast cancer patients.

Jegadeesh NK, Kim S, Prabhu RS, Oprea GM, Yu DS, Godette KG, Zelnak AB, Mister D, Switchenko JM, Torres MA.

Ann Surg Oncol. 2015 Apr;22(4):1088-94. doi: 10.1245/s10434-014-4252-y. Epub 2014 Dec 4.

19.

Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.

Knoop AS, Lænkholm AV, Jensen MB, Nielsen KV, Andersen J, Nielsen D, Ejlertsen B; Danish Breast Cancer Cooperative Group.

Eur J Cancer. 2014 May;50(8):1412-21. doi: 10.1016/j.ejca.2014.02.022. Epub 2014 Mar 24.

PMID:
24675287
20.

Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.

Hattangadi-Gluth JA, Wo JY, Nguyen PL, Abi Raad RF, Sreedhara M, Niemierko A, Freer PE, Georgian-Smith D, Bellon JR, Wong JS, Smith BL, Harris JR, Taghian AG.

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1185-91. doi: 10.1016/j.ijrobp.2011.02.061. Epub 2011 May 19.

Supplemental Content

Support Center